Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma:a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
- Author:
Jae Min LEE
1
;
Jung Yoon CHOI
;
Kyung Taek HONG
;
Hyoung Jin KANG
;
Hee Young SHIN
;
Hee Jo BAEK
;
Seongkoo KIM
;
Jae Wook LEE
;
Nack-Gyun CHUNG
;
Bin CHO
;
Seok-Goo CHO
;
Kyung Mi PARK
;
Eu Jeen YANG
;
Young Tak LIM
;
Jin Kyung SUH
;
Sung Han KANG
;
Hyery KIM
;
Kyung-Nam KOH
;
Ho Joon IM
;
Jong Jin SEO
;
Hee Won CHO
;
Hee Young JU
;
Ji Won LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Kyung Duk PARK
;
Jeong Ok HAH
;
Min Kyoung KIM
;
Jung Woo HAN
;
Seung Min HAHN
;
Chuhl Joo LYU
;
Ye Jee SHIM
;
Heung Sik KIM
;
Young Rok DO
;
Jae Won YOO
;
Yeon Jung LIM
;
In-Sang JEON
;
Hee won CHUEH
;
Sung Yong OH
;
Hyoung Soo CHOI
;
Jun Eun PARK
;
Jun Ah LEE
;
Hyeon Jin PARK
;
Byung-Kiu PARK
;
Soon Ki KIM
;
Jae Young LIM
;
Eun Sil PARK
;
Sang Kyu PARK
;
Eun Jin CHOI
;
Young Bae CHOI
;
Jong Hyung YOON
;
Hoon KOOK
;
Author Information
- Publication Type:Original Article
- From:Journal of Korean Medical Science 2020;35(46):e393-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Hodgkin's lymphoma (HL) constitutes 10%–20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea.
Methods:We performed a multicenter, retrospective study of 224 patients aged < 25 years diagnosed with HL at 22 participating institutes in Korea from January 2007 to August 2016.
Results:A higher percentage of males was diagnosed at a younger age. Nodular sclerosis histopathological HL subtype was most common, followed by mixed cellularity subtype.Eighty-one (36.2%), 101 (45.1%), and 42 (18.8%) patients were classified into low, intermediate, and high-risk groups, respectively. Doxorubicin, bleomycin, vinblastine, dacarbazine was the most common protocol (n = 102, 45.5%). Event-free survival rate was 86.0% ± 2.4%, while five-year overall survival (OS) rate was 96.1% ± 1.4%: 98.7% ± 1.3%, 97.7% ± 1.6%, and 86.5% ± 5.6% in the low, intermediate, and high-risk groups, respectively (P = 0.021). Five-year OS was worse in patients with B-symptoms, stage IV disease, highrisk, splenic involvement, extra-nodal lymphoma, and elevated lactate dehydrogenase level.In multivariate analysis, B-symptoms and extra-nodal involvement were prognostic factors for poor OS. Late complications of endocrine disorders and secondary malignancy were observed in 17 and 6 patients, respectively.
Conclusion:This is the first study on the epidemiology and treatment outcomes of HL in children, adolescents, and young adults in Korea. Future prospective studies are indicated to develop therapies that minimize treatment toxicity while maximizing cure rates in children, adolescents, and young adults with HL.
